Arkolith/Insider Trading/RAPH/Form 4

Pilo Shlomo

Chief Executive Officer, Director, 10% OwnerRaphael Pharmaceutical Inc. (RAPH) · full profile →Form 4 · filed Mar 11, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2025Grant(A)200K$0.50$100K4.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2025Grant(A)100K—$01.1M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-022736) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML